As filed with the Securities and Exchange Commission on April 22, 2013

Registration No. 333 -

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

  

FORM S-8

REGISTRATION STATEMENT

under the

SECURITIES ACT OF 1933

 

 

INTERCEPT PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		22-3868459
(State or Other Jurisdiction		(I.R.S. Employer
of Incorporation or Organization)		Identification No.)

18 Desbrosses Street

New York, NY 10013

(646) 747-1000

(Address, Including Zip Code, of Principal Executive Offices)

 

INTERCEPT PHARMACEUTICALS, INC. 2012 EQUITY INCENTIVE PLAN

(Full Title of the Plan)

 

Mark Pruzanski, M.D.

President and Chief Executive Officer

Intercept Pharmaceuticals, Inc.

18 Desbrosses Street

New York, NY

(646) 747-1000

(Name, Address and Telephone Number, Including Area Code, of Agent for Service)

 

Copies to:

William T. Whelan, Esq.

Scott A. Samuels, Esq.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, Massachusetts 02111

(617) 542-6000

Facsimile: (617) 542-2241

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨		Accelerated filer ¨
Non-accelerated filer x	(Do not check if smaller reporting company)	Smaller reporting company ¨

 

CALCULATION OF REGISTRATION FEE

 

Title of Securities to be Registered		Amount to be Registered(1)		Proposed Maximum Offering Price Per Share(2)				Proposed Maximum Aggregate Offering Price(2)				Amount of Registration Fee
Common Stock, par value $0.001 per share		661,075 shares		$	31.07			$	20,539,600.25			$	2,801.61

 

(1)

The number of shares of common stock, par value $0.001 per share (“Common Stock”), of Intercept Pharmaceuticals, Inc. (the “Registrant”), stated above consists of additional shares of Common Stock reserved under the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the “2012 Plan”) as a result of the automatic increase in shares reserved under the 2012 Plan on January 1, 2013 pursuant to the terms thereof. The maximum number of shares which may be issued under the Plan is subject to adjustment in accordance with certain anti-dilution and other provisions of the Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be subject to grant or otherwise issuable after the operation of any such anti-dilution and other provisions.

 

(2)

Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price for the additional shares reserved for future grant or issuance under the 2012 Plan are based on the average of the high and the low sales prices of Registrant’s Common Stock as reported on The NASDAQ Global Market as of a date (April 19, 2013) within five business days prior to filing this Registration Statement.

 

 

 

 

EXPLANATORY NOTE

 

This Registration Statement registers additional securities of the same class as other securities for which the registration statement filed on Form S-8 (SEC File No. 333-184810) of the Registrant is effective. The information contained in the Registrant’s registration statement on Form S-8 (SEC File No. 333-184810) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

 

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8. Exhibits.

 

The Index of Exhibits immediately following the signatures to this Registration Statement is incorporated herein by reference.

 

 

SIGNATURES

 

The Registrant. Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New York, New York on April 22, 2013.

 

	INTERCEPT PHARMACEUTICALS, INC.
	By	/s/    Mark Pruzanski
		Mark Pruzanski, M.D.
		President and Chief Executive Officer

 

We the undersigned officers and directors of Intercept Pharmaceuticals, Inc., hereby severally constitute and appoint Mark Pruzanski, M.D. and Barbara Duncan, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Intercept Pharmaceuticals, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all such things in our name and behalf in our capacities as officers and directors to enable Intercept Pharmaceuticals, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature		Title		Date
/s/ Mark Pruzanski		President and Chief Executive Officer		April 22, 2013
Mark Pruzanski, M.D.		(Principal Executive Officer)
/s/ Barbara Duncan		Chief Financial Officer, Secretary and Treasurer		April 22, 2013
Barbara Duncan		(Principal Financial and Accounting Officer)
/s/ Lorenzo Tallarigo		Chairman of the Board of Directors		April 22, 2013
Lorenzo Tallarigo, M.D.
/s/ Paolo Fundaro		Director		April 22, 2013
Paolo Fundaro
/s/ Jonathan T. Silverstein		Director		April 22, 2013
Jonathan T. Silverstein
/s/ Klaus Veitinger		Director		April 22, 2013
Klaus Veitinger, M.D.
/s/ Nicole Williams		Director		April 22, 2013
Nicole Williams
/s/ Srinivas Akkaraju		Director		April 22, 2013
Srinivas Akkaraju

 

 

EXHIBIT INDEX

 

Exhibit
Number		Description
(5.1)		Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as to the legality of shares being registered.
(23.1)		Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in opinion of counsel filed as Exhibit 5.1).
(23.2)		Consent of KPMG LLP, independent registered public accounting firm.
(23.3)		Consent of EisnerAmper LLP, independent registered public accounting firm.
(24.1)		Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement).